RecoveryInvestigational

Dalargin

Intravenous, Intramuscular injection

Overview

Dalargin is a synthetic hexapeptide analog of leucine-enkephalin with enhanced metabolic stability due to D-amino acid substitutions. It acts as a selective delta opioid receptor agonist with peripheral and central effects, including modulation of stress responses, anti-inflammatory activity, and cytoprotection in gastrointestinal and vascular tissues.

Mechanism of Action

Unlike classical opioids, dalargin exhibits reduced central analgesic potency but pronounced tissue-protective properties..

Research Summary & Key Findings

Dalargin has been used clinically in Russia and some Eastern European countries for treatment of gastric ulcers, pancreatitis, and stress-related mucosal injury since the 1980s. Peer-reviewed evidence in Western literature is limited, with most data derived from Soviet-era clinical studies and pharmacological characterization in animal models.

Clinical Status

Investigational

Dalargin is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.

Administration Routes

IntravenousIntramuscular injection

Related Peptides in Recovery

Find a Provider

Find a verified provider who offers Dalargin therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Dalargin.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.